

16 Jun 2024 | News

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

by Brian Yang

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

XXXXXXXXXXCitelineXXXXXXXXXXXX

XXXXXXXXXXCitelineXXXXSarah Karlin-SmithXBrian YangXDexter YanXXXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXASCOXXXXXXXXXXXXXXXXXXXXLate Breaking AbstractsXXXXXXXXXX

XXXXXXXXXXXXXXXXXXXXXXXXXXXXGenefleetXKROCUSXXXXSimcereXXXXXX
SCORESXXXX

XXXXXXXXXXXXXXXXXXXXBIOXXXXSarahXXCitelineXXXXXXXXXXXXXXXXXXXXBIOXXJohn CrowleyXXXX
XXXXXXXXXXXXXXXXXXXXBIOSECURE ActXX
XXXXXXXXXXXXXXXXXXXX

In this mixed Chinese- and English-language episode of China Biotech Podcast, Dexter Yan discusses China-related highlights from the recent American Society of Clinical Oncology (ASCO) annual conference, where Chinese biotechs GeneFleet, *Simcere Pharmaceutical Group*, *Akeso Inc.* and *Jiangsu Hengrui Medicine Co., Ltd.* presented new clinical results in oncology.

In the second part, Sarah Karlin-Smith, a US-based reporter for Citeline Insights, shares updates on the BIOSECURE Act after covering the BIO annual conference in San Diego. What was the general feeling at the largest gathering for the US biotech sector and what are some of the responses from US biopharma manufacturers to prepare for the proposed eight-year timeframe to halt use of R&D contract and manufacturing services with “companies of concern”?

Sarah also takes a look at some of the potential outcomes for the legislation going forward.

Stories discussed in this podcast:

(Also see "[ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer](#)" - Scrip, 12 Jun, 2024.)

(Also see "[BIO Elevates State Policy, Patient Advocacy In Reorganization](#)" - Pink Sheet, 6 Jun, 2024.)

[Click here to explore this interactive content online](#) 